USP7 and cancer: To investigate whether USP7 knockdown could also sensitize cells from other cancer entities to PI3K pathway inhibition, we utilized the human CRC (Caco2-TA, LoVo-TA) and HCC (HEP-3B; HuH7-TA) cell lines harboring the constructs with strongest USP7 knockdown after 4 and 8 days of Dox treatment (Supplementary Figures S7C-S8C).